Biohaven

Read more
Vlad Coric's photo - CEO of Biohaven

CEO

Vlad Coric

CEO Approval Rating

92/100

Founded:

2013

Status:

PublicIndependent CompanyNYSEBHVN

BIOHAVEN TOP COMPETITORS OR ALTERNATIVES

RANK

COMPANY

CEO

CEO RATING

EMPLOYEES

FUNDING

REVENUE

Biohaven's company profile
Vlad Coric's photo - CEO of Biohaven

Vlad Coric

CEO

92/100
63
$748.3M
$189.5M
View Profile
1
Biohaven's Competitor - Covis Pharma logo
CEO Avatar

Michael Porter

CEO

88/100
90
- -
$57M
View Profile
2
Biohaven's Competitor - Neuropore logo
Douglas Bonhaus's photo - CEO of Neuropore

Douglas Bonhaus

CEO

89/100
25
$20.9M
$4.1M
View Profile
3
Biohaven's Competitor - MODAG logo
Torsten Matthias's photo - CEO of MODAG

Torsten Matthias

CEO

90/100
90
$16.3M
View Profile
4
Biohaven's Competitor - ProMIS logo
Elliot Goldstein's photo - President & CEO of ProMIS

Elliot Goldstein

President & CEO

87/100
1
$53.3M
$ < 1M
View Profile
5
Biohaven's Competitor - Dart NeuroScience logo
Kenneth E. Johns's photo - CEO of Dart NeuroScience

Kenneth E. Johns

CEO

69/100
53
- -
$12.3M
View Profile
6
Biohaven's Competitor - Allergan logo
CEO Avatar

CEO

- -
16,900
$31.1M
$16B
View Profile
7
Biohaven's Competitor - Zosano Pharma logo
Steven Lo's photo - President & CEO of Zosano Pharma

Steven Lo

President & CEO

83/100
53
$215.5M
$ < 1M
View Profile
8
Biohaven's Competitor - Denali logo
Ryan Watts's photo - President & CEO of Denali

Ryan Watts

President & CEO

100/100
179
$597M
$357.1M
View Profile
9
Biohaven's Competitor - Alector logo
Arnon Rosenthal's photo - President & CEO of Alector

Arnon Rosenthal

President & CEO

82/100
78
$407.5M
$24.6M
View Profile
10
Biohaven's Competitor - Alzheon logo
Martin Tolar's photo - President & CEO of Alzheon

Martin Tolar

President & CEO

85/100
30
$94.3M
$8M
View Profile
11
Biohaven's Competitor - Yumanity logo
Richard Peters's photo - President & CEO of Yumanity

Richard Peters

President & CEO

90/100
44
$103.8M
$6M
View Profile
12
Biohaven's Competitor - Tiburio logo
Abraham N Ceesay's photo - President & CEO of Tiburio

Abraham N Ceesay

President & CEO

89/100
15
$36M
$ < 1M
View Profile

Missing a competitor? Contribute!

Covis Pharma is seen as one of Biohaven's biggest rivals. Covis Pharma is headquartered in Baarn, Utrecht, and was founded in 2011. Like Biohaven, Covis Pharma also works within the Pharmaceuticals sector. Covis Pharma generates 30% the revenue of Biohaven.

Neuropore is seen as one of Biohaven's top competitors. Neuropore was founded in 2008, and its headquarters is in San Diego, California. Neuropore operates in the Biotechnology industry. Neuropore has 38 fewer employees than Biohaven.

MODAG is one of Biohaven's top rivals. MODAG is a Private company that was founded in Wendelsheim, Rhineland-Palatinate in 2013. MODAG operates in the Biotechnology industry. MODAG has 27 more employees vs. Biohaven.

Biohaven Quarterly and Annual Revenue

Trailing 12-Months Trend (TTM)

Annual Revenue

$189.5M

Biohaven's revenue is the ranked 3rd among it's top 10 competitors. The top 10 competitors average 1.3B. Over the last four quarters, Biohaven's revenue has grown by 426.1%. Specifically, in Q2 2021's revenue was $92.9M; in Q1 2021, it was $43.8M; in Q4 2020, it was $35.1M; in Q3 2020, Biohaven's revenue was $17.7M.

Biohaven Acquisitions

COMPANY ACQUIRED
ACQUISITION DATE
AMOUNT
DESCRIPTION
Kleo Pharmaceuticals, Inc.

Jan 2021

Source »
undisclosed
Kleo is a biotechnology company that develops and commercializes therapeutics for the treatment of cancer and infectious diseases.

These are all the companies that Biohaven has acquired. Biohaven's latest acquisition was Kleo Pharmaceuticals, Inc. in Jan 2021. Kleo is a biotechnology company that develops and commercializes therapeutics for the treatment of cancer and infectious diseases.

Biohaven Funding History

Since Biohaven was founded in 2013, it has participated in 3 rounds of funding. In total Biohaven has raised $748.3M. Biohaven's last funding round was on Aug 2020 for a total of $500.0M

ROUND

FUNDING DATE

AMOUNT

INVESTORS

Debt
Aug 2020
$500M
IPO
May 2017
$168.3M
-
Equity
Oct 2016
$80M

Since Biohaven was founded in 2013, it has participated in 3 rounds of funding. In total Biohaven has raised $748.3M. Biohaven's last funding round was on Aug 2020 for a total of $500.0M

Biohaven Investments

COMPANY

DESCRIPTION

AMOUNT

INVESTMENT DATE

ROUND

EXIT DATE

Kleo is a biotechnology company that develops and commercializes therapeutics for the treatment of cancer and infectious diseases.
$13.5M
Aug 28, 2016
-

These are all the companies that Biohaven has invested in. Biohaven's latest investment was Kleo in Aug 28,. Kleo is a biotechnology company that develops and commercializes therapeutics for the treatment of cancer and infectious diseases.

Biohaven News

October 1, 2021MarketScreener

Amendment to Sixth Street Financing Agreement (Form 8-K)

(marketscreener.com) Amendment to Sixth Street Financing Agreement On September 30, 2021, Biohaven Ph... See more »
September 28, 2021Zacks

Biohaven (BHVN) Phase III Multiple System Atrophy Study Fails

Biohaven's (BHVN) myeloperoxidase enzyme inhibitor, verdiperstat fails to statistically differentiate... See more »
September 27, 2021PharmaLive

Biohaven's drug candidate for neurological disorder fails study

Biohaven Pharmaceutical Holding Co. Ltd. said on Sept. 27 the company's drug candidate, verdiperstat,... See more »
September 27, 2021Endpoints News

Biohaven turns out a dud in fatal neurodegenerative disease, casting doubt on drug's chances in ALS

Irfan Qureshi With one migraine drug on the market, Biohaven has gone big with its next phase of grow... See more »
August 24, 2021FiercePharma

Biohaven points up Nurtec dual-migraine approval with growing stable of celebrity users

Biohaven points up Nurtec dual-migraine approval with growing stable of celebrity users bbulik Mon, 0... See more »
August 9, 2021Citybizlist

Biohaven Reports Second Quarter 2021 Financial Results

Biohaven Pharmaceutical Holding Company Ltd. (NYSE: BHVN), a biopharmaceutical company with a portfol... See more »
August 9, 2021Zacks

Biohaven (BHVN) Q2 Earnings Miss, Nurtec Uptake Still Strong

Biohaven's (BHVN) sole approved drug, Nurtec ODT for treating migraine continues to demonstrate stron... See more »

Biohaven Press Releases

July 21, 2020centralcharts

Biohaven Completes Enrollment Ahead of Timelines in International Phase 3 Clinical Trial of Verdiperstat in Multiple System Atrophy

Biohaven Completes Enrollment Ahead of Timelines in International Phase 3 Clinical Trial of Verdipers... See more »
July 15, 2020PR Newswire

After Living with Migraine for Years, Khlo Kardashian Leads Biohaven's Take Back Today Campaign to Empower People with Migraine

NEW HAVEN, Conn., July 15, 2020 /PRNewswire/ -- Khloé Kardashian joins efforts with Biohaven Pharmace... See more »
March 17, 2020PRWeb

Catalent Partners with Biohaven on New Fast-Dissolve Migraine Treatment

Catalent, the leading global provider of advanced delivery technologies, development, and manufacturi... See more »
February 25, 2020StreetInsider

Biohaven Pharmaceuticals Reports Fourth Quarter And Full Year 2019 Financial Results And Recent Business Developments

NEW HAVEN, Conn., Feb. 25, 2020 /PRNewswire/Â --Â Biohaven Pharmaceutical Holding Company Ltd. (NYSE:... See more »
February 10, 2020centralcharts

Biohaven's Rimegepant Named To Cortellis 2020 Potential Blockbuster "Drugs to Watch" List

Biohaven's Rimegepant Named To Cortellis 2020 Potential Blockbuster "Drugs to Watch" List PR Newswire... See more »
November 5, 2019centralcharts

Biohaven Completes Enrollment In Pivotal Phase 2/3 Alzheimer's Disease Clinical Trial Of Troriluzole

Biohaven Completes Enrollment In Pivotal Phase 2/3 Alzheimer's Disease Clinical Trial Of Troriluzole ... See more »
November 5, 2019StreetInsider

Thomas J. Lynch, Jr., MD, Appointed As Kleo Chairman Of The Board

NEW HAVEN, Conn., Nov. 4, 2019 /PRNewswire/ --Â Biohaven Pharmaceutical Holding Company Ltd. (NYSE: B... See more »

Biohaven Videos

July 29, 2021Biohaven Youtube Channel

"Biohaven Internship Program" on YOUTUBE

July 20, 2021Biohaven Youtube Channel

"Barbara's Journey with MSA" on YOUTUBE

June 29, 2021Biohaven Youtube Channel

"OCD Stories - Malena" on YOUTUBE

June 29, 2021Biohaven Youtube Channel

"OCD Stories - Rachel" on YOUTUBE

June 29, 2021Biohaven Youtube Channel

"OCD Stories - Valerie" on YOUTUBE

June 25, 2021Biohaven Youtube Channel

"OCD Stories - Chris" on YOUTUBE

Social Media

Biohaven Headquarters

215 Church Street

New Haven, Connecticut06510

203-404-0410

Driving Directions »

Trending Companies

Biohaven Summary

ABOUT

Overview

Biohaven is a pharmaceutical company that researches and develops novel drugs for the treatment of neurological and neuropsychiatric diseases. Biohaven was founded in 2013. Biohaven's headquarters is located in New Haven, Connecticut, USA 06510. Bioh...

CEO

Biohaven's CEO, Vlad Coric, currently has an approval rating of 92%. Biohaven's primary competitors are Covis Pharma, Neuropore & MODAG.

Frequently Asked Questions about Biohaven

  1. When was Biohaven founded?

    Biohaven was founded in 2013
  2. Who is Biohaven's CEO?

    Biohaven's CEO is Vlad Coric
  3. How much revenue does Biohaven generate?

    Biohaven generates $189.5M in revenue
  4. How much funding does Biohaven have?

    Biohaven has historically raised $748.3M in funding
  5. Where is Biohaven's headquarters?

    Biohaven's headquarters is in New Haven Connecticut, USA
  1. How many employees does Biohaven have?

    Biohaven has 63 employees
  2. What sector does Biohaven operate in?

    Biohaven is in Biotechnology, Pharmaceuticals
  3. Who are Biohaven's competitors?

    Biohaven's top competitors are Covis Pharma, Neuropore, MODAG
  4. Who has Biohaven invested in?

    Biohaven's has invested in companies such as Kleo